- Home
- EQR vs ILMN Comparison
EQR vs ILMN Comparison
Compare EQR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- ILMN
- Stock Information
- Founded
- EQR 1993
- ILMN 1998
- Country
- EQR United States
- ILMN United States
- Employees
- EQR N/A
- ILMN N/A
- Industry
- EQR Real Estate Investment Trusts
- ILMN Medical Specialities
- Sector
- EQR Real Estate
- ILMN Health Care
- Exchange
- EQR Nasdaq
- ILMN Nasdaq
- Market Cap
- EQR 27.9B
- ILMN 23.6B
- IPO Year
- EQR 1993
- ILMN 2000
- Fundamental
- Price
- EQR $72.78
- ILMN $147.64
- Analyst Decision
- EQR Buy
- ILMN Buy
- Analyst Count
- EQR 19
- ILMN 19
- Target Price
- EQR $75.22
- ILMN $162.67
- AVG Volume (30 Days)
- EQR 1.4M
- ILMN 2.1M
- Earning Date
- EQR 01-28-2025
- ILMN 02-06-2025
- Dividend Yield
- EQR 3.71%
- ILMN N/A
- EPS Growth
- EQR 35.67
- ILMN N/A
- EPS
- EQR 2.44
- ILMN N/A
- Revenue
- EQR $2,940,829,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- EQR N/A
- ILMN N/A
- Revenue Next Year
- EQR $4.01
- ILMN $4.28
- P/E Ratio
- EQR $29.87
- ILMN N/A
- Revenue Growth
- EQR 3.33
- ILMN N/A
- 52 Week Low
- EQR $57.33
- ILMN $97.36
- 52 Week High
- EQR $78.83
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- EQR 42.24
- ILMN 56.37
- Support Level
- EQR $72.90
- ILMN $138.88
- Resistance Level
- EQR $73.97
- ILMN $151.75
- Average True Range (ATR)
- EQR 1.09
- ILMN 4.96
- MACD
- EQR -0.33
- ILMN 0.76
- Stochastic Oscillator
- EQR 4.65
- ILMN 81.01
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.